Search | WHO COVID-19 Research Database

1.

A comparison of peripheral blood stem cell collection outcomes for multiple myeloma, mobilization matters in the era of IMiD induction

Chandler, T.; Parrish, C.; Karakantza, M.; Carmichael, J.; Pawson, D.; Cook, G.; Seymour, F..

eJHaem ; 2023.

Article in English | EMBASE | ID: covidwho-2313518

2.

FEASIBILITY OF HAEMATOPOIETIC STEM CELL MOBILIZATION AFTER CONSOLIDATION WITH GEMTUZUMAB OZOGAMICIN AND INTERMEDIATE-DOSES ARA-C AND DAUNORUBICIN IN AML

Perrone, S.; La Barbera, E. O.; Capria, S.; Marchesi, F.; Trisolini, S. M.; Sorella, S.; Antonacci, M.; Minotti, C.; Filipponi, V.; Bafti, M. S.; Equitani, F.; Scerpa, M. C.; Martelli, M.; Cimino, G..

HemaSphere ; 6:2386-2387, 2022.

Article in English | EMBASE | ID: covidwho-2032147

3.

IMPACT OF DARATUMUMAB (DARA) ADMINISTRATION DURING TRANSPLANT- ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) INDUCTION ON STEM CELL (SC) MOBILIZATION COUNT AND POST-TRANSPLANT ENGRAFTMENT

Crusoe, E. Q.; Moura, A.; Chaves, M.; Salvino, M.; Santos, J.; Santos, H.; Santos, A.; Lucas, L.; Leal, J.; Arruda, M. G..

Hematology, Transfusion and Cell Therapy ; 43:S261-S262, 2021.

Article in English | EMBASE | ID: covidwho-1859624

4.

A monthly roundup of key articles in other journals

McOmish, C..

Transfusion ; 61(8):2229-2231, 2021.

Article in English | EMBASE | ID: covidwho-1745852

5.

Mobilization and collection of hematopoietic stem cells in poorly mobilizable patients with multiple myeloma and lymphoma across Germany: Interim analysis of the OPTIMOB study

Wehler, D.; Bittrich, M.; Kriegsmann, K.; Tietze-Bürger, C.; Grube, M.; Vucinic, V.; Burchert, A.; Kunz, C.; Schmidt-Hieber, M.; Rank, A.; Kröger, N..

Oncology Research and Treatment ; 44(SUPPL 2):198, 2021.

Article in English | EMBASE | ID: covidwho-1623613

6.

Impact of Induction Treatment on Stem Cell Collection: A COVID Related Study

Rybinski, B.; Badros, A. Z.; Rapoport, A. P.; Kocoglu, M. H..

Blood ; 138:4848, 2021.

Article in English | EMBASE | ID: covidwho-1582306

7.

Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients

De Queiroz Crusoe, E.; Leal, J.; Salvino, M. A.; Lucas, L. F.; Santos, J. A.; Santos, H. H. D. M.; Almeida, A. D. M.; Santos, A. D. S.; Chaves, M.; Santos, M. M.; Silva, S. Q.; Vieira, L. D. O.; Fonseca, C. A.; Adorno, E.; Hungria, V.; Arruda, M. D. G. B..

Blood ; 138:3943, 2021.

Article in English | EMBASE | ID: covidwho-1582283

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL